Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

LXRX | Lexicon Pharmaceuticals Inc

Index	RUT	P/E	-	EPS (ttm)	-0.68	Insider Own	1.98%	Shs Outstand	244.93M	Perf Week	-16.24%
Market Cap	240.03M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	-	Shs Float	240.09M	Perf Month	-42.01%
Income	-130.72M	PEG	-	EPS next Q	-0.21	Inst Own	77.34%	Short Float / Ratio	7.87% / 12.05	Perf Quarter	-56.64%
Sales	0.41M	P/S	585.44	EPS this Y	-30.38%	Inst Trans	17.97%	Short Interest	18.90M	Perf Half Y	-60.16%
Book/sh	0.76	P/B	1.29	EPS next Y	6.53%	ROA	-60.93%	Target Price	6.33	Perf Year	-59.17%
Cash/sh	1.05	P/C	0.93	EPS next 5Y	-	ROE	-101.65%	52W Range	1.00 - 3.79	Perf YTD	-48.69%
Dividend	-	P/FCF	-	EPS past 5Y	12.05%	ROI	-44.98%	52W High	-74.14%	Beta	1.19
Dividend %	-	Quick Ratio	10.09	Sales past 5Y	26.76%	Gross Margin	-16.42%	52W Low	-2.00%	ATR	0.09
Employees	135	Current Ratio	10.10	Sales Q/Q	805.71%	Oper. Margin	-31557.60%	RSI (14)	25.02	Volatility	9.91% 7.52%
Optionable	Yes	Debt/Eq	0.57	EPS Q/Q	-33.48%	Profit Margin	-32038.97%	Rel Volume	2.27	Prev Close	1.02
Shortable	Yes	LT Debt/Eq	0.56	Earnings	Aug 03 AMC	Payout	-	Avg Volume	1.57M	Price	0.98
Recom	2.00	SMA20	-24.96%	SMA50	-38.93%	SMA200	-55.64%	Volume	991,733	Change	-3.92%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26
Aug-05-16	Reiterated	Wedbush	Outperform	$30 → $31
Aug-02-16	Initiated	Citigroup	Buy	$21
Mar-02-16	Reiterated	Wedbush	Outperform	$26 → $28

Show Previous Ratings

Sep-28-23 09:00AM	Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 (GlobeNewswire) -9.09%
Sep-26-23 09:00AM	Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) (GlobeNewswire) +10.38%
Sep-20-23 12:28PM	15 Best Affordable Stocks To Buy Under $5 (Insider Monkey)
Sep-14-23 09:40PM	Insider Buying: Jeffrey Wade Acquires 10,000 Shares of Lexicon Pharmaceuticals Inc (LXRX) (GuruFocus.com)
Sep-07-23 04:30PM	Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference (GlobeNewswire)
09:00AM	Loading…
09:00AM	Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Aug-21-23 09:00AM	Lexicon to Present Analyses of INPEFA (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023 (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-08-23 09:00AM	Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure (GlobeNewswire) +7.06%
Aug-04-23 09:12AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 49%, while individual investors hold 25% (Simply Wall St.)
Aug-03-23 05:15PM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Lexicon: Q2 Earnings Snapshot (AP Finance)
04:01PM	Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-23 04:01PM	Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023 (GlobeNewswire)
08:00AM	Lexicon Elects Diane E. Sullivan to Board of Directors (GlobeNewswire)
06:52AM	Loading…
Jun-30-23 06:52AM	Daily Vickers Top Buyers & Sellers for 06/30/2023 (Argus Research) +5.53%
Jun-27-23 06:46AM	Daily Vickers Top Buyers & Sellers for 06/27/2023 (Argus Research)
Jun-23-23 08:45PM	Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development (GlobeNewswire)
09:24AM	Daily Vickers Top Buyers & Sellers for 06/23/2023 (Argus Research)
Jun-20-23 08:00AM	Lexicon to Present Study Results Relating to LX9211 and INPEFA (Sotagliflozin) at the American Diabetes Associations 83rd Scientific Sessions (GlobeNewswire)
Jun-15-23 05:00PM	UPDATE: Lexicon Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure (GlobeNewswire)
Jun-06-23 04:01PM	Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference (GlobeNewswire)
Jun-05-23 04:01PM	Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares (GlobeNewswire) -7.47%
Jun-04-23 07:00AM	The Word Is, 'Lexicon' Is Worth a Trade (TheStreet.com)
Jun-02-23 09:21AM	Why Lexicon Pharmaceuticals Stock Crashed This Week (Motley Fool)
Jun-01-23 11:35AM	Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More (Zacks) -17.88%
08:00AM	Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
May-31-23 04:01PM	Lexicon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.79%
May-26-23 04:25PM	UPDATE 2-U.S. FDA approves Lexicon Pharma's drug for heart failure (Reuters) +9.66%
04:08PM	U.S. FDA approves Lexicon Pharma's heart failure drug (Reuters)
04:05PM	Loading…
04:05PM	Lexicon Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure (GlobeNewswire)
May-22-23 07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com) +6.64%
May-11-23 06:50AM	Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You? (Motley Fool)
May-10-23 04:30PM	New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure (GlobeNewswire)
May-04-23 10:05AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2023 Earnings Call Transcript (Insider Monkey) +12.41%
May-03-23 11:45AM	Q1 2023 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +15.13%
May-02-23 04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 04:00PM	Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023 (GlobeNewswire)
Apr-22-23 08:15AM	Should You Buy This Growth Stock Right Now Before It Potentially Doubles? (Motley Fool)
Apr-21-23 09:00AM	Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023 (GlobeNewswire)
Apr-17-23 04:00PM	Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +11.62%
Mar-06-23 06:00AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-04-23 12:00PM	New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiologys 72nd Annual Scientific Session Together With World Heart Federations World Congress of Cardiology (GlobeNewswire)
10:00AM	Lexicon Reveals INTO THE DARK Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization (GlobeNewswire)
Mar-03-23 07:07AM	Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +22.94%
Mar-02-23 04:00PM	Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-23 05:00PM	Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023 (GlobeNewswire)
Feb-20-23 08:00AM	New Analyses of Sotagliflozin to Be Presented at the American College of Cardiologys 72nd Annual Scientific Session Together With World Heart Federations World Congress of Cardiology (GlobeNewswire)
Feb-01-23 07:56AM	Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48% ownership, institutions own 26% (Simply Wall St.)
Jan-06-23 04:05PM	Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference (GlobeNewswire)
Dec-29-22 06:52PM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2022 Earnings Call Transcript (Insider Monkey) +7.22%
Dec-22-22 09:22AM	Lexicon Pharma's Pain Candidate Fails In Postherpetic Neuralgia Study (Benzinga)
Dec-21-22 04:30PM	Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia (GlobeNewswire)
Nov-28-22 08:00AM	Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -5.16%
Nov-15-22 10:00AM	Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study (Benzinga)
Nov-14-22 04:03PM	Lexicons LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit (GlobeNewswire)
Nov-12-22 07:28AM	Lexicon Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-11-22 08:58AM	Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference (GlobeNewswire) +5.80%
Nov-09-22 04:01PM	Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update (GlobeNewswire)
Nov-08-22 08:58AM	Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit (GlobeNewswire)
Nov-06-22 05:29PM	New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozins Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure (GlobeNewswire)
Nov-05-22 10:35AM	New Analysis of SCORED Trial Demonstrates Sotagliflozins Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (GlobeNewswire)
Nov-04-22 08:58AM	Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022 (GlobeNewswire)
Oct-31-22 08:59AM	New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022 (GlobeNewswire)
Oct-24-22 08:59AM	Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022 (GlobeNewswire)
Oct-02-22 01:00PM	New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozins Effect on Reducing Recurrent Heart Failure Events (GlobeNewswire)
Sep-20-22 08:59AM	Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy (GlobeNewswire)
Aug-22-22 04:05PM	Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease (GlobeNewswire) -6.51%
Aug-05-22 04:59PM	Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement (GlobeNewswire) +5.20%
Aug-02-22 04:01PM	Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +9.70%
Jul-29-22 08:00AM	Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022 (GlobeNewswire)
Jul-28-22 07:00AM	Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement (GlobeNewswire) -26.61%
Jul-27-22 04:01PM	Lexicon Announces Proposed Public Offering Of Common Stock (GlobeNewswire)
07:59AM	Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure (GlobeNewswire)
Jun-29-22 04:01PM	Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy (GlobeNewswire)
Jun-06-22 02:16PM	Do Institutions Own Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares? (Simply Wall St.)
Jun-01-22 08:00AM	Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference (GlobeNewswire)
May-31-22 08:00AM	Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure (GlobeNewswire)
May-11-22 06:35AM	7 Biotech Stocks With Key Catalysts for May (InvestorPlace) -6.86%
May-05-22 06:00AM	Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update (GlobeNewswire)
Apr-29-22 08:00AM	Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022 (GlobeNewswire)
Apr-07-22 08:00AM	Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire) +10.70%
Apr-04-22 08:00AM	Lexicon Welcomes New Guidelines for the Management of Heart Failure (GlobeNewswire) +12.00%
Apr-02-22 12:15PM	Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22) (GlobeNewswire)
Mar-21-22 08:01AM	New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiologys 71st Annual Scientific Session (ACC.22) (GlobeNewswire)
Mar-18-22 09:57AM	Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization (Benzinga)
Mar-17-22 04:14PM	Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin (GlobeNewswire)
Mar-08-22 04:34AM	We Think Lexicon Pharmaceuticals (NASDAQ:LXRX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-04-22 05:10AM	The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals (Zacks)
Mar-03-22 06:21PM	Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More (Zacks)
Feb-28-22 04:54PM	Why Lexicon Pharmaceuticals Was Plunging on Monday (Motley Fool) -27.37%
06:01AM	Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update (GlobeNewswire)
06:00AM	Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022 (GlobeNewswire)
Feb-25-22 09:03PM	Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022 (GlobeNewswire)
Jan-13-22 09:00AM	Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-22 04:05PM	Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-22 10:46AM	Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug (Zacks)
Dec-30-21 04:05PM	Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes (GlobeNewswire)
Nov-15-21 04:30PM	Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
Nov-14-21 08:35AM	Lexicons Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data (GlobeNewswire)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WADE JEFFREY L	President and CFO	Sep 14	Buy	1.38	10,000	13,800	264,341	Sep 14 05:05 PM
McDermott Wendy	VP, Human Resources	Aug 04	Buy	1.84	6,000	11,040	28,478	Aug 07 04:13 PM
COATS LONNEL	Chief Executive Officer	Jun 29	Buy	2.16	10,000	21,600	814,359	Jun 29 04:13 PM
COATS LONNEL	Chief Executive Officer	Jun 26	Buy	2.18	10,000	21,792	804,359	Jun 26 04:04 PM
COATS LONNEL	Chief Executive Officer	Jun 23	Buy	2.50	10,000	24,950	794,359	Jun 26 04:04 PM
McDermott Wendy	VP, Human Resources	Jun 23	Buy	2.43	10,000	24,300	22,478	Jun 27 04:22 PM
COATS LONNEL	Chief Executive Officer	Jun 22	Buy	2.31	40,000	92,400	784,359	Jun 22 04:01 PM
WADE JEFFREY L	President and CFO	Jun 20	Buy	2.33	12,000	28,000	254,341	Jun 20 04:10 PM
Artal International S.C.A.	Director	Jun 05	Buy	2.60	27,775,050	72,215,130	78,634,381	Jun 05 04:46 PM
Swain Judith L	Director	May 21	Option Exercise	0.00	9,302	0	40,332	May 22 04:07 PM
Palantoni Frank	Director	May 21	Option Exercise	0.00	9,302	0	40,332	May 22 04:06 PM
SOBECKI CHRISTOPHER J	Director	May 21	Option Exercise	0.00	9,302	0	159,023	May 22 04:06 PM
NIES ALAN S	Director	May 21	Option Exercise	0.00	9,302	0	41,046	May 22 04:05 PM
DEBBANE RAYMOND	Director	May 21	Option Exercise	0.00	9,302	0	340,847	May 22 04:03 PM
LEFKOWITZ ROBERT J MD	Director	May 21	Option Exercise	0.00	9,302	0	40,332	May 22 04:04 PM
BARKER SAM L	Director	May 21	Option Exercise	0.00	9,302	0	79,617	May 22 04:02 PM
Amouyal Philippe	Director	May 21	Option Exercise	0.00	9,302	0	40,332	May 22 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXRX | Lexicon Pharmaceuticals Inc

Upgrade your FINVIZ experience